Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 18
HOS-086279 · Präparat HOS-083284
Haloperidol, risperidone, thioridazine Ritonavir dosed as an antiretroviral agent is likely to inhibit CYP2D6 and as a result
is expected to increase concentrations of haloperidol, risperidone and thioridazine.
Careful monitoring of therapeutic and adverse effects is recommended when these
medicines are concomitantly administered with antiretroviral doses of ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): risperidone (HOS-086280) thioridazine (HOS-086281) haloperidol (HOS-085602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 8e761d348fd212b36bc78ffd76ef90c5ee11cf475302161ba9d45775577f515a · Zeichen 37794–38290 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 51
HOS-086459 · Präparat HOS-083284
Haloperidol, risperidone, thioridazine Ritonavir dosed as an antiretroviral agent is likely to inhibit CYP2D6 and as a result is
expected to increase concentrations of haloperidol, risperidone and thioridazine. Careful
monitoring of therapeutic and adverse effects is recommended when these medicines are
concomitantly administered with antiretroviral doses of ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): risperidone (HOS-086280) thioridazine (HOS-086281) haloperidol (HOS-085602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f0a67fe46d125e481cb4cea4661c4de785f314c1c7ed4a14b0d5054d39eb1dfd · Zeichen 39585–40081 im Abschnitt
Wechselwirkungen · Yentreve
YENTREVE 20 mg hard gastro-resistant capsules YENTREVE 40 mg hard gastro-resistant capsules · Abschnitt 4.5 · PDF-Seite 7
HOS-112874 · Präparat HOS-093777
Medicinal products metabolised by CYP2D6: Duloxetine is a moderate inhibitor of CYP2D6. When
duloxetine was administered at a dose of 60 mg twice daily with a single dose of desipramine, a
CYP2D6 substrate, the AUC of desipramine increased 3-fold. The co-administration of duloxetine
(40 mg twice daily) increases steady state AUC of tolterodine (2 mg twice daily) by 71 %, but does
not affect the pharmacokinetics of its active 5-hydroxyl metabolite and no dosage adjustment is
recommended. Caution is advised if YENTREVE is co-administered with medicinal products that are
predominantly metabolised by CYP2D6 (risperidone, tricyclic antidepressants [TCAs] such as
nortriptyline, amitriptyline, and imipramine) particularly if they have a narrow therapeutic index (such
as flecainide, propafenone and metoprolol).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nortriptyline (HOS-086245) propafenone (HOS-084530) tolterodine (HOS-087792) amitriptyline (HOS-085911) desipramine (HOS-086249) flecainide (HOS-086203) imipramine (HOS-085907) risperidone (HOS-086280) metoprolol (HOS-090094)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-09T15:33:00Z · SHA-256 d927c7a519b8bbcba3c7ad828fbbce3643ea8a3886fcc0403d91cbec6695f99d · Passage f5263b2aae78af8828902f00ed3e0c2dc4fa81db18866a0b8f1f78e73aa8af66 · Zeichen 2181–2995 im Abschnitt
Wechselwirkungen · Cymbalta
Cymbalta 30 mg hard gastro-resistant capsules Cymbalta 60 mg hard gastro-resistant capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-113277 · Präparat HOS-093901
Medicinal products metabolised by CYP2D6: Duloxetine is a moderate inhibitor of CYP2D6. When
duloxetine was administered at a dose of 60 mg twice daily with a single dose of desipramine, a
CYP2D6 substrate, the AUC of desipramine increased 3-fold. The co-administration of duloxetine (40
mg twice daily) increases steady state AUC of tolterodine (2 mg twice daily) by 71 %, but does not
affect the pharmacokinetics of its active 5-hydroxyl metabolite and no dosage adjustment is
recommended. Caution is advised if Cymbalta is co-administered with medicinal products that are
predominantly metabolised by CYP2D6 (risperidone, tricyclic antidepressants [TCAs] such as
nortriptyline, amitriptyline, and imipramine) particularly if they have a narrow therapeutic index (such
as flecainide, propafenone and metoprolol).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nortriptyline (HOS-086245) propafenone (HOS-084530) tolterodine (HOS-087792) amitriptyline (HOS-085911) desipramine (HOS-086249) flecainide (HOS-086203) imipramine (HOS-085907) risperidone (HOS-086280) metoprolol (HOS-090094)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-09T15:40:00Z · SHA-256 a3b2a486f9b4069e76d38032cad9e45c893ee290991d9c0e8b3ea325ef1c101c · Passage 184748d3a5fcda9339ead3f2521f29c9a83708c878d80bf6315817d557c04e72 · Zeichen 2367–3181 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 19–20
HOS-116394 · Präparat HOS-094447
19
ANTIPSYCHOTICS/NEUROLEPTICS
Quetiapine Not studied. Boosted PREZISTA is Concomitant administration of
expected to increase these antipsychotic boosted PREZISTA and quetiapine
plasma concentrations. is contraindicated as it may
(CYP3A inhibition) increase quetiapine-related
toxicity. Increased concentrations
of quetiapine may lead to coma
(see section 4.3).
Perphenazine Not studied. Boosted PREZISTA is A dose decrease may be needed for
Risperidone expected to increase these antipsychotic these drugs when co-administered
Thioridazine plasma concentrations. with boosted PREZISTA.
(CYP3A, CYP2D6 and/or P-gp
Lurasidone inhibition) Concomitant administration of
Pimozide boosted PREZISTA and
Sertindole lurasidone, pimozide or sertindole
is contraindicated (see section 4.3).
β-BLOCKERS
Carvedilol Not studied. Boosted PREZISTA is Clinical monitoring is
Metoprolol expected to increase these β-blocker recommended when
Timolol plasma concentrations. co-administering boosted
(CYP2D6 inhibition) PREZISTA with β-blockers. A
lower dose of the β-blocker should
be considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. Boosted PREZISTA can be Clinical monitoring of therapeutic
Diltiazem expected to increase the plasma and adverse effects is
Felodipine concentrations of calcium channel recommended when these
Nicardipine blockers. medicines are concomitantly
Nifedipine (CYP3A and/or CYP2D6 inhibition) administered with boosted
Verapamil PREZISTA.
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of boosted
metabolised by CYP3A ritonavir 100 mg capsules twice daily PREZISTA and corticosteroids (all
(including were co-administered with 50 g routes of administration) that are
betamethasone, intranasal fluticasone propionate (4 times metabolised by CYP3A may
budesonide, fluticasone, daily) for 7 days in healthy subjects, increase the risk of development of
mometasone, prednisone, fluticasone propionate plasma systemic corticosteroid effects,
triamcinolone) concentrations increased significantly, including Cushing’s syndrome and
whereas the intrinsic cortisol levels adrenal suppression.
decreased by approximately 86% (90%
CI 82-89%). Greater effects may be Co-administration with CYP3A-
expected when fluticasone is inhaled. metabolised corticosteroids is not
Systemic corticosteroid effects including recommended unless the potential
Cushing’s syndrome and adrenal benefit to the patient outweighs the
suppression have been reported in risk, in which case patients should
patients receiving ritonavir and inhaled or be monitored for systemic
intranasally administered fluticasone. The corticosteroid effects.
effects of high fluticasone systemic
exposure on ritonavir plasma levels are Alternative corticosteroids which
unknown. are less dependent on CYP3A
metabolism e.g. beclomethasone
Other corticosteroids: interaction not should be considered, particularly
studied. Plasma concentrations of these for long term use.
medicinal products may be increased
when co-administered with boosted
PREZISTA, resulting in reduced serum
cortisol concentrations.
Dexamethasone Not studied. Dexamethasone may Systemic dexamethasone should
(systemic) decrease plasma concentrations of be used with caution when
darunavir. combined with boosted
(CYP3A induction) PREZISTA.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) fluticasone propionate (HOS-086331) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) lead (HOS-085592) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 06bb26e6737c57cc3c74485aceb2076b3feb5ff5bad566ac99081f05e0924029 · Zeichen 52002–57572 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 61–62
HOS-116527 · Präparat HOS-094447
61
Perphenazine Not studied. PREZISTA is expected to A dose decrease may be needed for
Risperidone increase these antipsychotic plasma these drugs when co-administered
Thioridazine concentrations. with PREZISTA co-administered
(CYP3A, CYP2D6 and/or P-gp with low dose ritonavir.
inhibition)
Lurasidone Concomitant administration of
Pimozide PREZISTA with low dose
Sertindole ritonavir and lurasidone, pimozide
or sertindole is contraindicated
(see section 4.3).
β-BLOCKERS
Carvedilol Not studied. PREZISTA is expected to Clinical monitoring is
Metoprolol increase these β-blocker plasma recommended when
Timolol concentrations. co-administering PREZISTA with
(CYP2D6 inhibition) β-blockers. A lower dose of the
β-blocker should be considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. PREZISTA co-administered Clinical monitoring of therapeutic
Diltiazem with low dose ritonavir can be expected and adverse effects is
Felodipine to increase the plasma concentrations of recommended when these
Nicardipine calcium channel blockers. medicines are concomitantly
Nifedipine (CYP3A and/or CYP2D6 inhibition) administered with PREZISTA with
Verapamil low dose ritonavir.
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of PREZISTA
metabolised by CYP3A ritonavir 100 mg capsules twice daily with low dose ritonavir and
(including were co-administered with 50 g corticosteroids (all routes of
betamethasone, intranasal fluticasone propionate (4 times administration) that are
budesonide, fluticasone, daily) for 7 days in healthy subjects, metabolised by CYP3A may
mometasone, prednisone, fluticasone propionate plasma increase the risk of development of
triamcinolone) concentrations increased significantly, systemic corticosteroid effects,
whereas the intrinsic cortisol levels including Cushing’s syndrome and
decreased by approximately 86% (90% adrenal suppression.
CI 82-89%). Greater effects may be
expected when fluticasone is inhaled. Co-administration with CYP3A-
Systemic corticosteroid effects including metabolised corticosteroids is not
Cushing’s syndrome and adrenal recommended unless the potential
suppression have been reported in benefit to the patient outweighs the
patients receiving ritonavir and inhaled or risk, in which case patients should
intranasally administered fluticasone. The be monitored for systemic
effects of high fluticasone systemic corticosteroid effects.
exposure on ritonavir plasma levels are
unknown. Alternative corticosteroids which
are less dependent on CYP3A
Other corticosteroids: interaction not metabolism e.g. beclomethasone
studied. Plasma concentrations of these should be considered, particularly
medicinal products may be increased for long term use.
when co-administered with PREZISTA
with low dose ritonavir, resulting in
reduced serum cortisol concentrations.
Dexamethasone Not studied. Dexamethasone may Systemic dexamethasone should
(systemic) decrease plasma concentrations of be used with caution when
darunavir. combined with PREZISTA
(CYP3A induction) co-administered with low dose
ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) fluticasone propionate (HOS-086331) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 8b9ea54ec289adeef1a2f9f81165d44d84f0b8d5433cec6f77b7df8c89fd8286 · Zeichen 43290–48378 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 101–102
HOS-116617 · Präparat HOS-094447
101
ANTIPSYCHOTICS/NEUROLEPTICS
Quetiapine Not studied. Boosted PREZISTA is Concomitant administration of
expected to increase these antipsychotic boosted PREZISTA and quetiapine
plasma concentrations. is contraindicated as it may
(CYP3A inhibition) increase quetiapine-related
toxicity. Increased concentrations
of quetiapine may lead to coma
(see section 4.3).
Perphenazine Not studied. Boosted PREZISTA is A dose decrease may be needed for
Risperidone expected to increase these antipsychotic these drugs when co-administered
Thioridazine plasma concentrations. with boosted PREZISTA.
(CYP3A, CYP2D6 and/or P-gp
Lurasidone inhibition) Concomitant administration of
Pimozide boosted PREZISTA and
Sertindole lurasidone, pimozide or sertindole
is contraindicated (see section 4.3).
β-BLOCKERS
Carvedilol Not studied. Boosted PREZISTA is Clinical monitoring is
Metoprolol expected to increase these β-blocker recommended when
Timolol plasma concentrations. co-administering boosted
(CYP2D6 inhibition) PREZISTA with β-blockers. A
lower dose of the β-blocker should
be considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. Boosted PREZISTA can be Clinical monitoring of therapeutic
Diltiazem expected to increase the plasma and adverse effects is
Felodipine concentrations of calcium channel recommended when these
Nicardipine blockers. medicines are concomitantly
Nifedipine (CYP3A and/or CYP2D6 inhibition) administered with boosted
Verapamil PREZISTA.
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of boosted
metabolised by CYP3A ritonavir 100 mg capsules twice daily PREZISTA and corticosteroids (all
(including were co-administered with 50 g routes of administration) that are
betamethasone, intranasal fluticasone propionate (4 times metabolised by CYP3A may
budesonide, fluticasone, daily) for 7 days in healthy subjects, increase the risk of development of
mometasone, prednisone, fluticasone propionate plasma systemic corticosteroid effects,
triamcinolone) concentrations increased significantly, including Cushing’s syndrome and
whereas the intrinsic cortisol levels adrenal suppression.
decreased by approximately 86% (90%
CI 82-89%). Greater effects may be Co-administration with CYP3A-
expected when fluticasone is inhaled. metabolised corticosteroids is not
Systemic corticosteroid effects including recommended unless the potential
Cushing’s syndrome and adrenal benefit to the patient outweighs the
suppression have been reported in risk, in which case patients should
patients receiving ritonavir and inhaled or be monitored for systemic
intranasally administered fluticasone. The corticosteroid effects.
effects of high fluticasone systemic
exposure on ritonavir plasma levels are Alternative corticosteroids which
unknown. are less dependent on CYP3A
metabolism e.g. beclomethasone
Other corticosteroids: interaction not should be considered, particularly
studied. Plasma concentrations of these for long term use.
medicinal products may be increased
when co-administered with boosted
PREZISTA, resulting in reduced serum
cortisol concentrations.
Dexamethasone Not studied. Dexamethasone may Systemic dexamethasone should
(systemic) decrease plasma concentrations of be used with caution when
darunavir. combined with boosted
(CYP3A induction) PREZISTA.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) fluticasone propionate (HOS-086331) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) lead (HOS-085592) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage ccb6e0bf9fbd4db134b19a5c68f5c32c6656fffa35e00c9b9b966f86c2226743 · Zeichen 51473–57044 im Abschnitt
Gegenanzeigen · Invega
INVEGA 3 mg prolonged-release tablets INVEGA 6 mg prolonged-release tablets INVEGA 9 mg prolonged-release tablets INVEGA 12 mg prolonged-release tablets · Abschnitt 4.3 · PDF-Seite 4
HOS-208663 · Präparat HOS-154161
Hypersensitivity to the active substance, risperidone, or to any of the excipients listed in section 6.1.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): risperidone (HOS-086280)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-12T09:16:00Z · SHA-256 c022336c81d7daff47a10cc72695ac049d82faed32c71ea4b5bbe029107608a3 · Passage 835cb9b6b49f71fd655d6a640c182602a6b0a5e3d7f0799811a3800abcc1b32a · Zeichen 0–105 im Abschnitt
Wechselwirkungen · Invega
INVEGA 3 mg prolonged-release tablets INVEGA 6 mg prolonged-release tablets INVEGA 9 mg prolonged-release tablets INVEGA 12 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-208680 · Präparat HOS-154161
Concomitant use of INVEGA with risperidone
Concomitant use of INVEGA with oral risperidone is not recommended as paliperidone is the active
metabolite of risperidone and the combination of the two may lead to additive paliperidone exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): risperidone (HOS-086280) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-12T09:16:00Z · SHA-256 c022336c81d7daff47a10cc72695ac049d82faed32c71ea4b5bbe029107608a3 · Passage 62887a9651b8baee92b91ec0fb857afafe360ce74bf05402bf054b4c8ff8c4e3 · Zeichen 4184–4424 im Abschnitt
Gegenanzeigen · Xeplion
Xeplion 25 mg prolonged release suspension for injection Xeplion 50 mg prolonged release suspension for injection Xeplion 75 mg prolonged release suspension for injection Xeplion 100 mg prolonged release suspension for injection Xeplion 150 mg prolonged release suspension for injection · Abschnitt 4.3 · PDF-Seite 6
HOS-124221 · Präparat HOS-095825
Hypersensitivity to the active substance, to risperidone or to any of the excipients listed in section 6.1.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): risperidone (HOS-086280)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage 3aaa8378617816a7c2264d1804a7693720d3363be2d3c79a585815c4193816e9 · Zeichen 0–107 im Abschnitt
Gegenanzeigen · Xeplion
Xeplion 150 mg and Xeplion 100 mg prolonged release suspension for injection · Abschnitt 4.3 · PDF-Seite 25
HOS-124269 · Präparat HOS-095825
Hypersensitivity to the active substance, to risperidone or to any of the excipients listed in section 6.1.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): risperidone (HOS-086280)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage 3aaa8378617816a7c2264d1804a7693720d3363be2d3c79a585815c4193816e9 · Zeichen 0–107 im Abschnitt
Wechselwirkungen · Xeplion
Xeplion 25 mg prolonged release suspension for injection Xeplion 50 mg prolonged release suspension for injection Xeplion 75 mg prolonged release suspension for injection Xeplion 100 mg prolonged release suspension for injection Xeplion 150 mg prolonged release suspension for injection · Abschnitt 4.5 · PDF-Seite 10
HOS-124242 · Präparat HOS-095825
Concomitant use of Xeplion with risperidone or with oral paliperidone
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): risperidone (HOS-086280)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage 67b213eca3d7f85a70b52f875712fc3098f4369816a54f82018263772d6ac432 · Zeichen 3883–3952 im Abschnitt
Wechselwirkungen · Xeplion
Xeplion 25 mg prolonged release suspension for injection Xeplion 50 mg prolonged release suspension for injection Xeplion 75 mg prolonged release suspension for injection Xeplion 100 mg prolonged release suspension for injection Xeplion 150 mg prolonged release suspension for injection · Abschnitt 4.5 · PDF-Seite 10
HOS-124243 · Präparat HOS-095825
Since paliperidone is the major active metabolite of risperidone, caution should be exercised when
Xeplion is co-administered with risperidone or with oral paliperidone for extended periods of time.
Safety data involving concomitant use of Xeplion with other antipsychotics is limited.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): risperidone (HOS-086280)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage 75e9eaa5fdc4852cc23d9707819f5967f3c3e11be5d7145c76abfd16af1bbec6 · Zeichen 3954–4239 im Abschnitt
Wechselwirkungen · Xeplion
Xeplion 150 mg and Xeplion 100 mg prolonged release suspension for injection · Abschnitt 4.5 · PDF-Seite 29–30
HOS-124283 · Präparat HOS-095825
29
Concomitant use of Xeplion with risperidone or with oral paliperidone
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): risperidone (HOS-086280)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage d86608ff2f182f6e5d8efc82d7789e88342e511116f02b02bdffdcd1ada855b2 · Zeichen 3939–4012 im Abschnitt
Wechselwirkungen · Xeplion
Xeplion 150 mg and Xeplion 100 mg prolonged release suspension for injection · Abschnitt 4.5 · PDF-Seite 30
HOS-124284 · Präparat HOS-095825
Since paliperidone is the major active metabolite of risperidone, caution should be exercised when
Xeplion is co-administered with risperidone or with oral paliperidone for extended periods of time.
Safety data involving concomitant use of Xeplion with other antipsychotics is limited.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): risperidone (HOS-086280)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage 75e9eaa5fdc4852cc23d9707819f5967f3c3e11be5d7145c76abfd16af1bbec6 · Zeichen 4014–4299 im Abschnitt
Wechselwirkungen · Zytiga
ZYTIGA 250 mg tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-125282 · Präparat HOS-096037
Caution is advised when administering with medicinal products activated by or metabolised by
CYP2D6, particularly with medicinal products that have a narrow therapeutic index. Dose reduction of
medicinal products with a narrow therapeutic index that are metabolised by CYP2D6 should be
considered. Examples of medicinal products metabolised by CYP2D6 include metoprolol,
propranolol, desipramine, venlafaxine, haloperidol, risperidone, propafenone, flecainide, codeine,
oxycodone and tramadol (the latter three medicinal products requiring CYP2D6 to form their active
analgesic metabolites).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) codeine (HOS-090544) desipramine (HOS-086249) flecainide (HOS-086203) oxycodone (HOS-109487) risperidone (HOS-086280) venlafaxine (HOS-086573) haloperidol (HOS-085602) propranolol (HOS-084529) metoprolol (HOS-090094) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T14:31:00Z · SHA-256 1cd8edc18fae83339cc466c58b27be12ff13a584e8ad30419a21aea3ec2adf1f · Passage 0f93936cb2f4b0a901b74791dc0ebac57b0490ee048860943323df74f2965713 · Zeichen 1565–2156 im Abschnitt
Wechselwirkungen · Zytiga
ZYTIGA 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 29
HOS-125314 · Präparat HOS-096037
Caution is advised when administering with medicinal products activated by or metabolised by
CYP2D6, particularly with medicinal products that have a narrow therapeutic index. Dose reduction of
medicinal products with a narrow therapeutic index that are metabolised by CYP2D6 should be
considered. Examples of medicinal products metabolised by CYP2D6 include metoprolol,
propranolol, desipramine, venlafaxine, haloperidol, risperidone, propafenone, flecainide, codeine,
oxycodone and tramadol (the latter three medicinal products requiring CYP2D6 to form their active
analgesic metabolites).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) codeine (HOS-090544) desipramine (HOS-086249) flecainide (HOS-086203) oxycodone (HOS-109487) risperidone (HOS-086280) venlafaxine (HOS-086573) haloperidol (HOS-085602) propranolol (HOS-084529) metoprolol (HOS-090094) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T14:31:00Z · SHA-256 1cd8edc18fae83339cc466c58b27be12ff13a584e8ad30419a21aea3ec2adf1f · Passage 0f93936cb2f4b0a901b74791dc0ebac57b0490ee048860943323df74f2965713 · Zeichen 1565–2156 im Abschnitt
Wechselwirkungen · Mysimba
Mysimba 8 mg/90 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-130320 · Präparat HOS-096899
Co-administration of bupropion with drugs that are metabolised by CYP2D6 isozyme including
certain antidepressants (SSRIs and many tricyclic antidepressants, e.g. desipramine, imipramine,
paroxetine), antipsychotics (e.g., haloperidol, risperidone and thioridazine), beta-blockers (e.g.,
metoprolol) and Type 1C antiarrhythmics (e.g., propafenone and flecainide), should be approached
with caution and should be initiated at the lower end of the dose range of the concomitant medicinal
product. Although citalopram is not primarily metabolised by CYP2D6, in one study, bupropion
increased the Cmax and AUC of citalopram by 30% and 40%, respectively.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) citalopram (HOS-087802) propafenone (HOS-084530) desipramine (HOS-086249) flecainide (HOS-086203) imipramine (HOS-085907) risperidone (HOS-086280) thioridazine (HOS-086281) haloperidol (HOS-085602) metoprolol (HOS-090094)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-07T14:58:00Z · SHA-256 8d91203fd1313606105ccfcfeb588970833594eb1edb4edb571e8c8ed61c515c · Passage cd65a9952c510c78425f288878ffbcc66bc9158597a50f714a7a9b26d908a649 · Zeichen 1889–2538 im Abschnitt
Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-132861 · Präparat HOS-097310
Monitoring of QT-prolongation if
used concomitantly.
Bortezomib Bortezomib: Careful monitoring.
Busulfan AUC: ↑ 1.4-fold Dose adjustment of each medicinal
Docetaxel Imatinib: product may be required.
Imatinib AUC: ↑ 1.4-fold
Cabazitaxel Cmax: ↑ 1.3-fold
↑in plasma concentrations of
docetaxel have been observed
Potential ↑in plasma concentrations of
busulfan
Cabazitaxel
AUC: ↑ 1.3-fold
Paclitaxel Paclitaxel: Careful monitoring.
No change in plasma concentration were Dose adjustment of paclitaxel
shown with paclitaxel concentrate. No may be required.
studies were performed with albumin
bound nanoparticules.
Vincristine, vinblastine Potential ↑in plasma concentrations of Careful monitoring as it may cause
(vinca alkaloids) vinca alkaloids. an earlier onset and/or an increased
severity of side-effects.
Antipsychotics,
Anxiolytics and
Hypnotics
Triazolam AUC: ↑ have been observed Contraindicated due to the risk of
Alprazolam Cmax: ↑ have been observed potentially prolonged or increased
Midazolam oral sedation and respiratory depression
(see section 4.3).
Lurasidone Lurasidone: Contraindicated due to the increased
AUC: ↑ 9 fold risk of adverse reactions (see section
Cmax: ↑ 6 fold 4.3).
Pimozide Potential ↑in plasma concentrations of Contraindicated due to the risk of
pimozide. serious cardiovascular events
including QT prolongation (see
section 4.3).
Sertindole Potential ↑in plasma concentrations of Contraindicated due to the risk of QT
sertindole. prolongation (see section 4.3).
Quetiapine Quetiapine: Contraindicated as it may increase
AUC: ↑ 6.2-fold quetiapine-related toxicity (see
Cmax: ↑ 3.4-fold section 4.3).
Haloperidol Potential ↑in plasma concentrations of Not recommended due to the
haloperidol. increased risk of QT prolongation
and extrapyramidal symptoms. It
may be necessary to reduce
haloperidol dosage.
Reboxetine Reboxetine: Not recommended because of
AUC: ↑ 1.5-fold of both enantiomers reboxetine narrow’s therapeutic
margin.
Midazolam IV Midazolam: Careful monitoring.
AUC: ↑ 1.6-fold Dose adjustment of midazolam IV
may be required.
11
Medicinal product by Expected effect on drug levels Recommendation for co-
therapeutic area administration
Buspirone Potential ↑in plasma concentrations of Careful monitoring.
buspirone. Dose adjustement of buspirone
may be required.
Aripiprazole Aripiprazole Careful monitoring.
AUC: ↑ 1.6-fold Aripiprazole dose should be reduced
Cmax: ↑ 1.4-fold to approximatively one-half of its
prescribed dose.
Risperidone Potential ↑in AUC of risperidone: Careful monitoring. Dose adjustment
of risperidone may be required.
Antivirals products
Saquinavir Saquinavir: Contraindicated due to the risk of QT
(saquinavir/ritonavir AUC: ↔ prolongation (see section 4.3).
1000/100 mg bid) Cmax: ↔
Ketoconazole
AUC: ↑ 2.7-fold
Cmax:↑ 1.5-fold
(CYP3A4 enzyme inhibition by
ritonavir)
Paritaprevir: Contraindicated due to the increased
AUC: ↑2.2-fold risk of adverse reactions (see section
Cmax: ↑1.7-fold 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): aripiprazole (HOS-129408) sertindole (HOS-085601) quetiapine (HOS-086150) busulfan (HOS-115553) reboxetine (HOS-132863) alprazolam (HOS-086171) vinblastine (HOS-086220) risperidone (HOS-086280) vincristine (HOS-086219) imatinib (HOS-110212) docetaxel (HOS-084505) saquinavir (HOS-084522) bortezomib (HOS-110227) pimozide (HOS-085600) cabazitaxel (HOS-124028) buspirone (HOS-086325) paclitaxel (HOS-087959) haloperidol (HOS-085602) ritonavir (HOS-084521) paritaprevir (HOS-110301) lurasidone (HOS-086148) triazolam (HOS-086168) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage 143b60c2365c220e7ae1ab4873f027ce623544d65995b03a1aab29b618d47f97 · Zeichen 15667–21466 im Abschnitt
Wechselwirkungen · Duloxetine Zentiva
Duloxetine Zentiva 30 mg gastro-resistant hard capsules Duloxetine Zentiva 60 mg gastro-resistant hard capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-133014 · Präparat HOS-097350
Medicinal products metabolised by CYP2D6
Duloxetine is a moderate inhibitor of CYP2D6. When duloxetine was administered at a dose of 60 mg
twice daily with a single dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased
3-fold. The co-administration of duloxetine (40 mg twice daily) increases steady state AUC of
tolterodine (2 mg twice daily) by 71 %, but does not affect the pharmacokinetics of its active 5-
hydroxyl metabolite and no dosage adjustment is recommended. Caution is advised if duloxetine is co-
administered with medicinal products that are predominantly metabolised by CYP2D6 (risperidone,
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tolterodine (HOS-087792) desipramine (HOS-086249) risperidone (HOS-086280)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-11-29T16:00:00Z · SHA-256 a6188d2978ea09f7e5b7445a447f5e2a57efdecb0d31b2c6eef34f98353221c3 · Passage 052d36e07670b6a346a0c99f6a16088cd8966146a02a552f01abdb66b616ad6e · Zeichen 2365–2992 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.